Vascular tumors were not observed in other targeted combinations of tumor suppressor deletion using the same Cre driver line [41] including substitution of Ptpn12 deletion in this model by activation of MAPK signaling through the expression of a BRAF mutant allele (BRAF V600E; ARS and LMLC, unpublished data). This evidence concerns the gene PTPN12 and vascular neoplasm.